Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience

Affiliation auteurs!!!! Error affiliation !!!!
TitreGranulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience
Type de publicationJournal Article
Year of Publication2015
AuteursTerrier B, Dechartres A, Girard C, Jouneau S, Kahn J-E, Dhote R, Lazaro E, Cabane J, Papo T, Schleinitz N, Cohen P, Begon E, Belenotti P, Chauveau D, Diot E, Genereau T, Hamidou M, Hayem G, Le Guenno G, Le Guern V, Michel M, Moulis G, Puechal X, Riviere S, Samson M, Gonin F, Le Jeunne C, Corlieu P, Mouthon L, Guillevin L, Grp FVasculitis
JournalRHEUMATOLOGY
Volume54
Pagination1852-1857
Date PublishedOCT
Type of ArticleArticle
ISSN1462-0324
Mots-clésbronchial stenosis, dilatation, Granulomatosis with polyangiitis, Prosthesis, subglottic stenosis, tracheobronchial involvement
Résumé

Objectives. Tracheobronchial stenosis (TBS) is noted in 12-23% of patients with granulomatosis with polyangiitis (GPA), and includes subglottic stenosis and bronchial stenosis. We aimed to analyse the endoscopic management of TBS in GPA and to identify factors associated with the efficacy of endoscopic interventions. Methods. We conducted a French nationwide retrospective study that included 47 patients with GPA-related TBS. Results. Compared with patients without TBS, those with TBS were younger, more frequently female and had less frequent kidney, ocular and gastrointestinal involvement and mononeuritis multiplex. Endoscopic procedures included 137 tracheal and 50 bronchial interventions, mainly endoscopic dilatation, local steroid injection and conservative laser surgery, and less frequently stenting. After the first endoscopic procedure, the cumulative incidence of endoscopic treatment failure was 49% at 1 year, 70% at 2 years and 80% at 5 years. Factors significantly associated with a higher cumulative incidence of treatment failure were a shorter time from GPA diagnosis to endoscopic procedure [hazard ratio (HR) 1.08 (95% CI 1.01, 1.14); P = 0.01] and a bronchial stenosis [HR 1.96 (95% CI 1.28, 3.00); P = 0.002]. A prednisone dose 530 mg/day at the time of the procedure was associated with a lower cumulative incidence of treatment failure [HR 0.53 (95% CI 0.31, 0.89); P = 0.02]. Conclusion. TBS represents severe and refractory manifestations with a high rate of restenosis. High-dose systemic CSs at the time of the procedure and increased time from GPA diagnosis to bronchoscopic intervention are associated with a better event-free survival. In contrast, bronchial stenoses are associated with a higher rate of restenosis than subglottic stenosis.

DOI10.1093/rheumatology/kev129